FASEB :肾病患者新希望!抗肾纤维化的新工具出世!

2017-10-16 佚名 medicalxpress

间质性纤维化-造成过度的组织瘢痕的形成-导致人们易于形成慢性肾脏疾病。据报道,慢性肾脏疾病在美国的患病率近几年都在持续上升。

间质性纤维化-造成过度的组织瘢痕的形成-导致人们易于形成慢性肾脏疾病。据报道,慢性肾脏疾病在美国的患病率近几年都在持续上升。

RaymondHarris博士及其同事以前曾在研究糖尿病肾病和肾纤维化的发病机制中,成功的发现了糖尿病肾病和肾纤维化与表皮生长因子受体(EGFR)相关,但导致肾细胞持续的表皮生长因子受体(EGFR)活化(肾脏的特定区域)的作用机制目前尚不是很清楚。

现在,研究人员在小鼠模型中开发了肾近端小管上皮细胞持续性表皮生长因子受体(EGFR)激活的机制和模型。

他们证明小鼠也可以自行发展为自发的,进行性的肾小管间质性纤维化,其特征在于上皮细胞去分化(丧失“成熟”同一性),肌成纤维细胞和免疫细胞数量增加以及基质沉积增加。遗传或药理学抑制表皮生长因子受体(EGFR)活性,并降低其纤维化。

该研究报告在10月的“FASEB杂志”上发表并表明,肾脏持续的表皮生长因子受体(EGFR)活化导致肾纤维化。小鼠模型为科学家的研究提供了一个良好的平台,小鼠模型可用于识别抗纤维化的新靶点,并帮助研究人员开发了新的肾脏疾病的治疗策略。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057942, encodeId=7c62205e94227, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun May 27 02:42:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025824, encodeId=3557202582484, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Sep 18 04:42:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969958, encodeId=7a261969958a3, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sun Apr 01 16:42:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254239, encodeId=1f8425423909, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 19 08:20:43 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2018-05-27 gracezdd
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057942, encodeId=7c62205e94227, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun May 27 02:42:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025824, encodeId=3557202582484, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Sep 18 04:42:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969958, encodeId=7a261969958a3, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sun Apr 01 16:42:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254239, encodeId=1f8425423909, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 19 08:20:43 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057942, encodeId=7c62205e94227, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun May 27 02:42:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025824, encodeId=3557202582484, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Sep 18 04:42:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969958, encodeId=7a261969958a3, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sun Apr 01 16:42:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254239, encodeId=1f8425423909, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 19 08:20:43 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2018-04-01 珙桐
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057942, encodeId=7c62205e94227, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun May 27 02:42:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025824, encodeId=3557202582484, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Sep 18 04:42:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969958, encodeId=7a261969958a3, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sun Apr 01 16:42:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254239, encodeId=1f8425423909, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Oct 19 08:20:43 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-10-19 1ddf0692m34(暂无匿称)

    学习了,涨知识

    0

相关资讯

Sci Rep:科学家发现罕见肝肾疾病的新治疗靶点!

在联合国际研究中,大阪大学的研究人员与美国和西班牙的研究小组合作,发现称为PKHD1的单个基因的突变如何导致与罕见的肾脏和肝脏疾病相关的症状,ARPKD(常染色体隐性多囊肾病)。预计这些发现将导致针对该疾病的新型治疗策略。

Intern Med J:降压药物晚间给药对CKD合并高血压患者BP模式有何影响?

2017年8月,发表在《Intern Med J》的一项系统评价和荟萃分析调查了降压药物晚间给药方案对慢性肾病(CKD)合并高血压患者血压(BP)模式的影响。结果表明,晚间给药方案药物治疗可逆转高血压合并CKD患者的非杓型BP模式。

J AM SOC NEPHROL:肥胖者肾脏损伤机制及保护方法新进展

美国肾脏病学杂志(JASN)即将出版的研究结果指出了保护肥胖患者肾脏健康的潜在目标。该研究提供了由于肥胖导致的肾脏损伤发展背后的机制见解。

NEJM:利拉鲁肽可显著降低糖尿病肾病风险

研究表明,对于II糖尿病患者,服用利拉鲁肽可显著降低患者糖尿病肾病的发生和疾病进展

Ann Rheum Dis:预防老年人肾病:别嘌醇vs非布司他

2017年10月,发表在《Ann Rheum Dis》的一项由美国科学家进行的Medicare索赔数据分析,比较了别嘌醇和非布司他预防老年人肾病的有效性。

Am J Kidney Dis:社区药师培训和沟通网络能改善CKD患者药物相关问题吗?

2017年9月,发表在《Am J Kidney Dis》上的一项多中心、 整群随机对照试验研究了社区药师培训和沟通网络与慢性肾病(CKD)患者药物相关问题,研究结果表明为社区药师提供必要的临床数据以及相关的培训等,可以有效降低在结合了多学科医疗团队的门诊中随访的CKD患者药物相关问题的数量。